11:41 AM EDT, 08/04/2022 (MT Newswires) -- BriaCell Therapeutics Corp. (BCT.TO), a clinical-stage biotechnology company, said Thursday that it has secured an exclusive license from University of Maryland, Baltimore County to develop and commercialize Soluble CD80 as a biologic agent for the treatment of cancer.
Under the terms, BriaCell has the worldwide rights to develop and commercialize sCD80 while the university maintains ownership of the patents.
BriaCell will pay royalties to UMBC upon the commercialization of the product plus patent management costs.
"Our mission has been to develop safe and effective treatments for cancer patients who do not respond to existing treatments, and a transformational anti-cancer agent such as sCD80 may provide us with such an additional opportunity," BriaCell President and CEO Bill Williams said.
"Based on the promising data in animal studies, we plan to explore the potential use of sCD80 technology as a therapeutic agent in combination with our other immunotherapies or on its own. We look forward to accelerating the development of this novel anti-cancer agent to bring hope to patients who need it the most."
Price: 8.53, Change: +0.06, Percent Change: +0.71